Slide One
HYBRID 2021 PARTNERS

HYBRID 2021:

OUR PARTNERS

5 FORCES TO LAUNCH THE FIRST HYBRID MEETING

The health industry alliance for research and innovation (ARIIS), the alliance for life and health sciences (AVIESAN), the French union of pharmaceutical industries (Leem), the French investment bank (BpiFrance) and the association of French biotech companies (France Biotech) have joined forces to launch the first HYBRID meeting. The main idea is to bring a complete ecosystem from science to business thanks to these five partners.

This image for Image Layouts addon

ARIIS

Created in 2009, the health industry alliance for research and innovation (ARIIS) is made up of worldwide pharmaceutical and diagnostic companies. Reactive and agile , it’s a "start-up on the shoulders of giants". The Alliance organises preclinical research events and implements national industrial projects, in particular on health data. ARIIS is also in charge of national plans and roadmaps on various innovative subjects, with its historic partner, the public alliance Aviesan. For more information, visit our website

This image for Image Layouts addon

AVIESAN

Set up in April 2009, Aviesan was created out of a desire to improve French research performance by promoting consistency, creativity and excellence. This mission calls for scientific coordination of the main research themes, as well as operational coordination of projects, resources and funding.

For example, the purposes of Aviesan include life and health science research, transfer of fundamental knowledge to clinical application, facilitation of industrial partnerships or definition of shared standpoints in terms of European research and international cooperation.

These objectives are performed within 10 thematic multi-organization institutes (ITMOs) whose primary role is to chair the strategic debates within their own scientific community.

For more information, visit our website

This image for Image Layouts addon

LEEM

Leem is the French industry association which represents drug companies operating in France. On a national level, Leem acts as a champion and advocate for the pharmaceutical industry. In this capacity, it participates in numerous official, ministerial and inter-ministerial committees, is engaged in agreement-based policy with the State, negotiates with social partners and promotes ethical standards.
Leem is a member of the French Federation of Healthcare Industries (FEFIS) and of the French Enterprise Movement (MEDEF). At international level, Leem is a member of the European Federation of Pharmaceutical Associations and Industries (EFPIA) and of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

For more information, visit our website

This image for Image Layouts addon

BPIFrance

Bpifrance is the French national investment bank: it supports businesses – at every stage of their development – mainly micro-businesses, SMEs and mid-caps but we also accompany large caps that are considered important to the interests of France in terms of national economy, the territories or employment. We offer a continuum of solutions adapted to every key step in a business’ growth such as: business creation, financing, loans, guarantees, export insurance or equity investment. We are also the French agency for innovation, delivering massive programs to innovative entrepreneurs. Bpifrance also provides extrafinancial services (training, consultancy) to help entrepreneurs meet their challenges.

For more information, visit our website

This image for Image Layouts addon

France Biotech

Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies’ financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients.

For more information, visit our websit